OncoIndustry
FDA Accepts New Drug Application for Oral Investigational Treatment in RRMM – Bristol Myers Squibb
Bristol Myers Squibb/LinkedIn

FDA Accepts New Drug Application for Oral Investigational Treatment in RRMM – Bristol Myers Squibb

Bristol Myers Squibb, shared a post on LinkedIn:

“The U.S. FDA has accepted a New Drug Application for our second oral investigational treatment option for adult patients with relapsed or refractory multiple myeloma (RRMM).

We are steadfast in our mission to progress potential therapies that may improve outcomes for people living with RRMM. This acceptance, alongside our other recent milestones in RRMM, mark significant steps forward in our mission to develop new options for the people living with this disease.”

Other articles about FDA on OncoDaily.

BMS Bristol Myers Squibb cancer FDA New Drug Application OncoDaily Oncology U.S. FDA